Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Edwards Lifesciences CorpEW · Entity 3026 | CVP,Strategy/Corp Development | May 27, 2026 | May 27, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Edwards Lifesciences Corp
Report date May 27, 2026 · Filed May 27, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 98,611 |
Reported balance
After 2026-05-27 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2026-05-27 · Sale · Disposed 23,145 · Balance 98,611 F1: This transaction was executed in multiple trades at prices ranging from $86.27 to $86.57. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. |
| Common StockSEC Table I · non-derivative | Direct | 22,798.2532 |
Reported balance
Holding disclosure · report date 2026-05-27 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 22,798.2532 |
| Common StockSEC Table I · non-derivative | Indirect401(k) | 30,969.5756 |
Reported balance
Holding disclosure · report date 2026-05-27 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 30,969.5756 |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was executed in multiple trades at prices ranging from $86.27 to $86.57. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 27, 2026 Filed May 27, 2026 23:28 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 23,145 | $86.42 | $2,000,193.21 |
DisclosureSEC source: 0001225208-26-005610 · doc4.xml · nonDerivative · entry 1 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 98,611 F1 · price: This transaction was executed in multiple trades at prices ranging from $86.27 to $86.57. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 15, 2026 Filed May 18, 2026 21:28 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 8,000 | $81.82 | $654,572.80 |
DisclosureSEC source: 0001225208-26-005463 · doc4.xml · nonDerivative · entry 2 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: No plan indicated Ownership: Indirect · 401(k) Disclosed balance after: 30,969.5756 Read SEC document |
| May 15, 2026 Filed May 18, 2026 21:28 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 9,968 | $82.07 | $818,105.66 |
DisclosureSEC source: 0001225208-26-005463 · doc4.xml · nonDerivative · entry 1 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,798.2532 F1 · price: This transaction was executed in multiple trades at prices ranging from $81.975 to $82.260. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 11, 2026 Filed May 12, 2026 20:52 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionPerformance Rights · Derivative | 13,457 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-005171 · doc4.xml · derivative · entry 5 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,457 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On May 11, 2023, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 6, 2026, the Compensation and Governance Committee of the Board of Directors determined that 167.70% of the target number of shares would vest as of May 11, 2026, and the actual number of shares vested are reflected on this Form 4. F2 · derivative.expiration_date: These Performance Rights expire on May 10, 2030. Read SEC document |
| May 11, 2026 Filed May 12, 2026 20:52 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 7,469 | $79.96 | $597,221.24 |
DisclosureSEC source: 0001225208-26-005171 · doc4.xml · nonDerivative · entry 2 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,766.2532 Read SEC document |
| May 11, 2026 Filed May 12, 2026 20:52 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 13,457 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-005171 · doc4.xml · nonDerivative · entry 1 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,235.2532 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On May 11, 2023, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 6, 2026, the Compensation and Governance Committee of the Board of Directors determined that 167.70% of the target number of shares would vest as of May 11, 2026, and the actual number of shares vested are reflected on this Form 4. F1 · price: On May 11, 2023, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 6, 2026, the Compensation and Governance Committee of the Board of Directors determined that 167.70% of the target number of shares would vest as of May 11, 2026, and the actual number of shares vested are reflected on this Form 4. Read SEC document |
| May 08, 2026 Filed May 9, 2026 01:17 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 1,038 | $82.76 | $85,904.88 |
DisclosureSEC source: 0001225208-26-005048 · doc4.xml · nonDerivative · entry 3 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,778.2532 Read SEC document |
| May 07, 2026 Filed May 9, 2026 01:17 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantPerformance Rights · Derivative | 7,850 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-005048 · doc4.xml · derivative · entry 7 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,850 Underlying: Common Stock · 7,850 shares Expires not disclosed F3 · derivative.exercise_price: Reflects the target number of shares (the Target Award) covered by restricted stock units granted on May 7, 2026 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to vest on May 7, 2029. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 200% of the Target Awards. F3 · derivative.expiration_date: Reflects the target number of shares (the Target Award) covered by restricted stock units granted on May 7, 2026 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to vest on May 7, 2029. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 200% of the Target Awards. Read SEC document |
| May 07, 2026 Filed May 9, 2026 01:17 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantEmployee Stock Option (Right to Acquire) · Derivative | 44,000 | $0.00 Strike: $82.76 | $0.00 |
DisclosureSEC source: 0001225208-26-005048 · doc4.xml · derivative · entry 6 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,000 Underlying: Common Stock · 44,000 shares Expires 2033-05-06 F2 · derivative.exercise_date: These options were granted on May 7, 2026 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one month after the grant date in 36 approximately equal monthly installments. Read SEC document |
| May 07, 2026 Filed May 9, 2026 01:17 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 831 | $83.20 | $69,139.20 |
DisclosureSEC source: 0001225208-26-005048 · doc4.xml · nonDerivative · entry 2 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,816.2532 Read SEC document |
| May 07, 2026 Filed May 9, 2026 01:17 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantCommon Stock | 7,850 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-005048 · doc4.xml · nonDerivative · entry 1 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,647.2532 F1 · shares: These restricted stock units were granted on May 7, 2026 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Read SEC document |
| May 03, 2026 Filed May 4, 2026 23:29 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 469 | $83.98 | $39,386.62 |
DisclosureSEC source: 0001225208-26-004907 · doc4.xml · nonDerivative · entry 1 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,797.2532 Read SEC document |
| April 02, 2026 Filed Apr 2, 2026 21:13 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 22,680 | $0.00 Strike: $59.26 | $0.00 |
DisclosureSEC source: 0001225208-26-004249 · doc4.xml · derivative · entry 6 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 22,680 shares Expires 2026-05-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 02, 2026 Filed Apr 2, 2026 21:13 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 18,004 | $80.05 | $1,441,209.40 |
DisclosureSEC source: 0001225208-26-004249 · doc4.xml · nonDerivative · entry 3 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,266.2532 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2025. F3 · price: This transaction was executed in multiple trades at prices ranging from $79.490 to $80.435. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, uponrequest by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 02, 2026 Filed Apr 2, 2026 21:13 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 4,676 | $80.59 | $376,845.85 |
DisclosureSEC source: 0001225208-26-004249 · doc4.xml · nonDerivative · entry 2 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 39,270.2532 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2025. F2 · price: This transaction was executed in multiple trades at prices ranging from $80.510 to $80.660. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, uponrequest by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 02, 2026 Filed Apr 2, 2026 21:13 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 22,680 | $59.26 | $1,343,941.96 |
DisclosureSEC source: 0001225208-26-004249 · doc4.xml · nonDerivative · entry 1 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 43,946.2532 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2025. Read SEC document |
| March 02, 2026 Filed Mar 2, 2026 22:50 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 11,340 | $0.00 Strike: $59.26 | $0.00 |
DisclosureSEC source: 0001225208-26-002878 · doc4.xml · derivative · entry 5 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,680 Underlying: Common Stock · 11,340 shares Expires 2026-05-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 02, 2026 Filed Mar 2, 2026 22:50 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 11,340 | $85.93 | $974,430.32 |
DisclosureSEC source: 0001225208-26-002878 · doc4.xml · nonDerivative · entry 2 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,266.2532 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2025. F2 · price: This transaction was executed in multiple trades at prices ranging from $85.665 to $86.380. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, uponrequest by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 02, 2026 Filed Mar 2, 2026 22:50 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 11,340 | $59.26 | $671,970.98 |
DisclosureSEC source: 0001225208-26-002878 · doc4.xml · nonDerivative · entry 1 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 32,606.2532 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2025. Read SEC document |
| February 25, 2026 Filed Feb 27, 2026 00:33 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 24,000 | $83.84 | $2,012,076.00 |
DisclosureSEC source: 0001225208-26-002711 · doc4.xml · nonDerivative · entry 1 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,266.2532 F1 · price: This transaction was executed in multiple trades at prices ranging from $83.66 to $83.96. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, uponrequest by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. F2 · balance_after: Total reflects the correction of 13,396 shares held indirectly by the Reporting Person's trust, which were previously reported as directly held. Read SEC document |
| January 06, 2026 Filed Jan 6, 2026 23:02 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 11,340 | $0.00 Strike: $59.26 | $0.00 |
DisclosureSEC source: 0001225208-26-000378 · doc4.xml · derivative · entry 6 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 34,020 Underlying: Common Stock · 11,340 shares Expires 2026-05-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 06, 2026 Filed Jan 6, 2026 23:02 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 8,708 | $85.98 | $748,707.74 |
DisclosureSEC source: 0001225208-26-000378 · doc4.xml · nonDerivative · entry 3 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,870.2532 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2025. F3 · price: This transaction was executed in multiple trades at prices ranging from $85.40 to $86.10. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, uponrequest by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 06, 2026 Filed Jan 6, 2026 23:02 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 2,632 | $84.62 | $222,721.42 |
DisclosureSEC source: 0001225208-26-000378 · doc4.xml · nonDerivative · entry 2 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 40,578.2532 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2025. F2 · price: This transaction was executed in multiple trades at prices ranging from $84.39 to $85.25. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, uponrequest by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 06, 2026 Filed Jan 6, 2026 23:02 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 11,340 | $59.26 | $671,970.98 |
DisclosureSEC source: 0001225208-26-000378 · doc4.xml · nonDerivative · entry 1 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 43,210.2532 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2025. Read SEC document |
| December 12, 2025 Filed Dec 12, 2025 22:57 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GiftCommon Stock | 7,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-009935 · doc4.xml · nonDerivative · entry 3 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,870.2532 Read SEC document |
| December 12, 2025 Filed Dec 12, 2025 22:57 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 5,900 | $83.74 | $494,066.00 |
DisclosureSEC source: 0001225208-25-009935 · doc4.xml · nonDerivative · entry 2 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,970.2532 Read SEC document |
| December 12, 2025 Filed Dec 12, 2025 22:57 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 5,486.1175 | $83.79 | $459,681.79 |
DisclosureSEC source: 0001225208-25-009935 · doc4.xml · nonDerivative · entry 1 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,870.2532 Read SEC document |
| December 10, 2025 Filed Dec 10, 2025 23:58 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 11,340 | $0.00 Strike: $59.26 | $0.00 |
DisclosureSEC source: 0001225208-25-009841 · doc4.xml · derivative · entry 5 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 45,360 Underlying: Common Stock · 11,340 shares Expires 2026-05-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 10, 2025 Filed Dec 10, 2025 23:58 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 11,340 | $83.83 | $950,581.17 |
DisclosureSEC source: 0001225208-25-009841 · doc4.xml · nonDerivative · entry 2 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 50,356.3707 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2025. F2 · price: This transaction was executed in multiple trades at prices ranging from $83.465 to $84.100. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 10, 2025 Filed Dec 10, 2025 23:58 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 11,340 | $59.26 | $671,970.98 |
DisclosureSEC source: 0001225208-25-009841 · doc4.xml · nonDerivative · entry 1 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 61,696.3707 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2025. Read SEC document |
| June 02, 2025 Filed Jun 2, 2025 21:01 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 2,570 | $77.40 | $198,911.32 |
DisclosureSEC source: 0001225208-25-005628 · doc4.xml · nonDerivative · entry 1 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 50,356.3707 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2025. F2 · price: This transaction was executed in multiple trades at prices ranging from $77.36 to $77.68. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 11, 2025 Filed May 12, 2025 23:30 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 816 | $73.68 | $60,122.88 |
DisclosureSEC source: 0001225208-25-004999 · doc4.xml · nonDerivative · entry 1 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,926.3707 Read SEC document |
| May 08, 2025 Filed May 9, 2025 23:33 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantPerformance Rights · Derivative | 8,375 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-004939 · doc4.xml · derivative · entry 6 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,375 Underlying: Common Stock · 8,375 shares Expires not disclosed F3 · derivative.exercise_price: Reflects the target number of shares (the Target Award) covered by restricted stock unites granted on May 8, 2025 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to vest on May 8, 2028. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. F3 · derivative.expiration_date: Reflects the target number of shares (the Target Award) covered by restricted stock unites granted on May 8, 2025 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to vest on May 8, 2028. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. Read SEC document |
| May 08, 2025 Filed May 9, 2025 23:33 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantEmployee Stock Option (Right to Acquire) · Derivative | 47,000 | $0.00 Strike: $74.63 | $0.00 |
DisclosureSEC source: 0001225208-25-004939 · doc4.xml · derivative · entry 5 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,000 Underlying: Common Stock · 47,000 shares Expires 2032-05-07 F2 · derivative.exercise_date: These options were granted on May 8, 2025 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one month after the grant date in 36 approximately equal monthly installments. Read SEC document |
| May 08, 2025 Filed May 9, 2025 23:33 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantCommon Stock | 8,375 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-004939 · doc4.xml · nonDerivative · entry 2 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,742.3707 F1 · shares: These restricted stock units were granted on May 8, 2025 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Read SEC document |
| May 07, 2025 Filed May 9, 2025 23:33 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 851 | $74.92 | $63,756.92 |
DisclosureSEC source: 0001225208-25-004939 · doc4.xml · nonDerivative · entry 1 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,367.3707 Read SEC document |
| May 04, 2025 Filed May 5, 2025 23:29 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 508 | $75.65 | $38,430.20 |
DisclosureSEC source: 0001225208-25-004766 · doc4.xml · nonDerivative · entry 2 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,218.3707 Read SEC document |
| May 03, 2025 Filed May 5, 2025 23:29 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 480 | $75.65 | $36,312.00 |
DisclosureSEC source: 0001225208-25-004766 · doc4.xml · nonDerivative · entry 1 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,726.3707 Read SEC document |
| April 14, 2025 Filed Apr 14, 2025 22:18 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 9,500 | $0.00 Strike: $45.28 | $0.00 |
DisclosureSEC source: 0001225208-25-004230 · doc4.xml · derivative · entry 5 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,500 shares Expires 2025-05-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 14, 2025 Filed Apr 14, 2025 22:18 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 9,500 | $69.81 | $663,195.95 |
DisclosureSEC source: 0001225208-25-004230 · doc4.xml · nonDerivative · entry 2 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 47,206.3707 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $69.48 to $70.19. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 14, 2025 Filed Apr 14, 2025 22:18 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 9,500 | $45.28 | $430,128.65 |
DisclosureSEC source: 0001225208-25-004230 · doc4.xml · nonDerivative · entry 1 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 56,706.3707 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2023. Read SEC document |
| March 13, 2025 Filed Mar 13, 2025 21:41 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 9,500 | $0.00 Strike: $45.28 | $0.00 |
DisclosureSEC source: 0001225208-25-003388 · doc4.xml · derivative · entry 5 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,500 Underlying: Common Stock · 9,500 shares Expires 2025-05-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 13, 2025 Filed Mar 13, 2025 21:41 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 9,500 | $67.96 | $645,623.80 |
DisclosureSEC source: 0001225208-25-003388 · doc4.xml · nonDerivative · entry 2 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 46,935.7184 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $67.55 to $68.40. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 13, 2025 Filed Mar 13, 2025 21:41 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 9,500 | $45.28 | $430,128.65 |
DisclosureSEC source: 0001225208-25-003388 · doc4.xml · nonDerivative · entry 1 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 56,435.7184 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2023. Read SEC document |
| February 13, 2025 Filed Feb 13, 2025 23:04 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 6,500 | $0.00 Strike: $45.28 | $0.00 |
DisclosureSEC source: 0001225208-25-001711 · doc4.xml · derivative · entry 6 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,000 Underlying: Common Stock · 6,500 shares Expires 2025-05-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 13, 2025 Filed Feb 13, 2025 23:04 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 6,400 | $75.74 | $484,737.28 |
DisclosureSEC source: 0001225208-25-001711 · doc4.xml · nonDerivative · entry 3 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 46,935.7184 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $75.19 to $76.12. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 13, 2025 Filed Feb 13, 2025 23:04 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 100 | $76.26 | $7,626.00 |
DisclosureSEC source: 0001225208-25-001711 · doc4.xml · nonDerivative · entry 2 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 53,335.7184 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2023. Read SEC document |
| February 13, 2025 Filed Feb 13, 2025 23:04 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 6,500 | $45.28 | $294,298.55 |
DisclosureSEC source: 0001225208-25-001711 · doc4.xml · nonDerivative · entry 1 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 53,435.7184 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2023. Read SEC document |
| January 16, 2025 Filed Jan 16, 2025 22:07 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 5,000 | $0.00 Strike: $45.28 | $0.00 |
DisclosureSEC source: 0001225208-25-000684 · doc4.xml · derivative · entry 5 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,500 Underlying: Common Stock · 5,000 shares Expires 2025-05-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 16, 2025 Filed Jan 16, 2025 22:07 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 5,000 | $68.75 | $343,735.50 |
DisclosureSEC source: 0001225208-25-000684 · doc4.xml · nonDerivative · entry 2 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 46,935.7184 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $68.39 to $69.27. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.